During the last session, Elicio Therapeutics Inc. (NASDAQ:ELTX)’s traded shares were 0.41 million, with the beta value of the company hitting 0.61. At the end of the trading day, the stock’s price was $4.11, reflecting an intraday loss of -40.35% or -$2.78. The 52-week high for the ELTX share is $11.45, that puts it down -178.59 from that peak though still a striking 27.98% gain since the share price plummeted to a 52-week low of $2.96. The company’s market capitalization is $42.05M, and the average trade volume was 46.16K shares over the past three months.
Elicio Therapeutics Inc. (NASDAQ:ELTX) trade information
Elicio Therapeutics Inc. (ELTX) registered a -40.35% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -40.35% in intraday trading to $4.11, hitting a weekly high. The stock’s 5-day price performance is -38.47%, and it has moved by -46.06% in 30 days. Based on these gigs, the overall price performance for the year is -56.46%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Elicio Therapeutics Inc. (ELTX) estimates and forecasts
Statistics show that Elicio Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Elicio Therapeutics Inc. (ELTX) shares have gone down -47.04% during the last six months, with a year-to-date growth rate more than the industry average at 47.13% against 15.50.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 3.87%. While earnings are projected to return 47.20% in 2024.
ELTX Dividends
Elicio Therapeutics Inc. is due to release its next quarterly earnings in July. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
